Extended hormone therapy doesn't help some prostate cancer - WMBB News 13 - The Panhandle's News Leader

Extended hormone therapy doesn't help some prostate cancer patients

Updated:
© iStockphoto.com/ Lilli Day © iStockphoto.com/ Lilli Day
  • What's Going AroundMore>>

  • What's Going Around - April 16th

    What's Going Around - April 16th

    Wednesday, April 16 2014 11:16 AM EDT2014-04-16 15:16:33 GMT
    Sinus infections are going around this week. Nurse Practitioner Christy Johnson from Bay Medical-Sacred Heart Family Medicine says, "A sinus infection is inflammation or swelling of your sinuses. WhenMore >>
    A sinus infection can make a person feel miserable. More >>
  • What's Going Around - April 2nd

    What's Going Around - April 2nd

    Wednesday, April 2 2014 11:29 AM EDT2014-04-02 15:29:17 GMT
    It's allergy season, and a lot of patients are struggling right now. Dr. Brian Shaheen from Bay Medical-Sacred Heart Family Medicine says symptoms of allergies include: Congestion Clear nasal dischargeMore >>
    The first signs of pollen also signal the start of allergy season. More >>

MONDAY, Sept. 23 (HealthDay News) -- For men with intermediate-risk prostate cancer, long-term hormone therapy after radiation therapy provides no survival advantages compared with short-term hormone therapy, according to a new study.

Hormone therapy is used to reduce the levels of male hormones (androgens) such as testosterone, which can stimulate the growth of prostate cancer cells.

Researchers examined data from 133 men with intermediate-risk prostate cancer who underwent either long-term hormone therapy (59 patients) or short-term hormone therapy (74 patients) after receiving external beam radiation therapy.

Ten-year overall survival was 61 percent in the short-term group and 65 percent in the long-term group, which is not a statistically significant difference. Disease-specific survival was 96 percent in both groups.

The study was scheduled for presentation Monday at the annual meeting of the American Society for Radiation Oncology, in Atlanta.

"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS [overall survival] and DSS [disease-specific survival], indicate that this was clearly not the case," study lead author Dr. Amin Mirhadi, a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles, said in a society news release.

"This data supports administering less treatment, which will result in fewer side effects and reduce patients' overall health care costs," Mirhadi added.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Urology Care Foundation has more about hormone therapy for prostate cancer.

Copyright © 2013 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.